Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene

Treatment options in metastatic breast cancer are limited. New therapies preferable with predictive biomarkers are needed. The aim of these trials was to investigate if gene copy number of the topoisomerase 1 ...

Source: BMC Cancer - June 13, 2019 Category: Cancer & Oncology Authors: Iben K ümler, Eva Balslev, Jan Stenvang, Nils Brünner, Bent Ejlertsen, Erik Hugger Jakobsen and Dorte Lisbet Nielsen Tags: Research article Source Type: research